Immatics N.V. (IMTX)
|Net Income (ttm)||-35.20M|
|Trading Day||March 5|
|Day's Range||10.30 - 10.74|
|52-Week Range||8.66 - 17.25|
There are no news available yet.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets... [Read more...]
Dr. Harpreet Singh
|Stock Exchange |
|Ticker Symbol |
In 2019, Immatics's revenue was $18.45 million, an increase of 389.36% compared to the previous year's $3.77 million. Losses were -$31.57 million, 0.40% more than in 2018.
According to 5 analysts, the average rating for Immatics stock is "Strong Buy." The 12-month stock price forecast is 17.65, which is an increase of 69.22% from the latest price.